Cidara Therapeutics, Inc. (CDTX) Revenue History
Annual and quarterly revenue from 2012 to present
CDTX Revenue Over Time (2012–2024)
CDTX Revenue Growth History
2 of 5 years with positive growth- FY2012 revenue growth
- N/A
- FY2013 revenue growth
- N/A
- FY2014 revenue growth
- N/A
- FY2015 revenue growth
- N/A
- FY2016 revenue growth
- N/A
- FY2017 revenue growth
- N/A
- FY2018 revenue growth
- N/A
- FY2019 revenue growth
- N/A
- FY2020 revenue growth
- -42.3%
- FY2021 revenue growth
- +310.8%
- FY2022 revenue growth
- +30.0%
- FY2023 revenue growth
- -63.9%
- FY2024 revenue growth
- -94.5%
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2025 | $0 | — |
| Q2 2025 | $0 | -100.0% |
| Q1 2025 | $0 | -100.0% |
| Q4 2024 | $0 | -100.0% |
| Q3 2024 | $0 | -100.0% |
| Q2 2024 | $302K | -94.1% |
| Q1 2024 | $973K | -96.3% |
| Q4 2023 | $17.6M | +72.1% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2024)
CDTX's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
CDTX Revenue Analysis (2012–2024)
Current Revenue & Growth
As of June 21, 2026, Cidara Therapeutics, Inc. (CDTX) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q3 2025) recorded $0 in revenue
Historical Growth Trajectory
CDTX's 5-year compound annual growth rate (CAGR) stands at -42.9%, indicating revenue contraction over this period. The 3-year CAGR of -70.5% is below the 5-year average, signalling a growth deceleration in recent years. Cidara Therapeutics, Inc.'s highest annual revenue of $64.4 million was recorded in 2022.
Revenue by Segment
CDTX's revenue is primarily driven by Reportable Segment (100%). With over half of revenue concentrated in Reportable Segment, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including ACAD (+9.9% YoY), AGIO (+78.3% YoY), and ENTA (+7.4% YoY). Compare CDTX vs ACAD →
CDTX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CDTXCurrent | $0 | - | -42.9% | -13811.9% | |
 ACAD | $1.1B | +9.9% | +19.4% | 9.8% | |
 AGIO | $54M | +78.3% | - | -873.9% | |
 ENTA | $65M | +7.4% | -11.8% | -130.7% | |
 MGNX | $150M | +3.1% | +8.9% | -48.7% |
CDTX Historical Revenue Data (2012–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $1.3M | -94.5% | $1.3M | 100.0% | $-176,102,000 | -13811.9% |
| 2023 | $23.3M | -63.9% | $-13,480,000 | -57.9% | $-27,060,000 | -116.2% |
| 2022 | $64.4M | +30.0% | $64.4M | 100.0% | $-33,503,000 | -52.0% |
| 2021 | $49.6M | +310.8% | $-23,515,000 | -47.4% | $-42,255,000 | -85.2% |
| 2020 | $12.1M | -42.3% | $12.1M | 100.0% | $-71,849,000 | -595.4% |
| 2019 | $20.9M | - | $-25,486,000 | -121.9% | $-41,724,000 | -199.5% |
| 2018 | $0 | - | $-523,000 | - | $-63,285,000 | - |
| 2017 | $0 | - | $-667,000 | - | $-55,721,000 | - |
| 2016 | $0 | - | $-732,000 | - | $-48,436,000 | - |
| 2015 | $0 | - | $-461,000 | - | $-32,313,000 | - |
| 2014 | $0 | - | $0 | - | $-11,623,000 | - |
| 2013 | $0 | - | $0 | - | $-1,082,000 | - |
| 2012 | $0 | - | $0 | - | $-792,000 | - |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
14+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CDTX — Frequently Asked Questions
Quick answers to the most common questions about buying CDTX stock.
Is CDTX's revenue growth accelerating or slowing?
CDTX TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: -42.9%.
What is CDTX's revenue history from 2012 to 2026?
Cidara Therapeutics, Inc. (CDTX) revenue history spans 2012 to 2026. TTM revenue as of 2026 is $0.00, growing at N/A YoY. The 5-year CAGR is -42.9%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is CDTX's long-term revenue growth rate (CAGR)?
Cidara Therapeutics, Inc.'s 5-year revenue CAGR of -42.9% reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for CDTX.
Why does CDTX's quarterly revenue fluctuate?
CDTX quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Cidara Therapeutics, Inc.'s revenue data from 2012 to 2026 shows full historical quarterly detail on this page.
How is CDTX's revenue distributed by segment?
CDTX reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does CDTX's revenue compare to industry peers?
Cidara Therapeutics, Inc. (CDTX) with TTM revenue of $0.00 and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.